Conclusion
From this study, we can conclude that incorporation of KRN5500 into micelles did not reduce its antitumor activity. The most remarkable result is that incorporation of KRN5500 into polymeric micelles showed a substantial reduction of toxicity caused by organic solvents or chemicals for dissolving KRN5500.
Therefore we expect that KRN/m will be superior to KRN5500 for clinical use13.
More importantly the methodology of polymeric micelle drug carrier systems can be applied to other water-insoluble drugs used currently or in the future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Murad, AM. et al. 1993. Modified therapy with 5-fluorouracil, doxorubicin and Methotrexate in advanced gastric cancer. Cancer. 72: 37–41.
Glimelius, B. et al. 1994. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann. Oncol. 5: 189–190.
Scheithauer, W. et al. 1993. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Brit. Med. J. 306: 752–755.
Shimada, Y. et al. 1999. Phase III study UFT+MMC versus 5-FU+CDDP versus 5-FU alone in patients with advanced gastric cancer. JCOG study 9205. Proc Am Soc Clin Oncol. 18: 272a(abst 1043).
Matsumura, Y and Maeda, H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46: 6387–6392.
Maeda, H and Matsumura, Y. 1989. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier sys. 6: 193–210.
Duncan, R., Connors, and Maeda, H. 1996. Drug targeting in cancer therapy: the magic bullet, what next? J Drug Targeting 3: 317–319.
Matsumoto, K. et al. 1984. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem. 96: 739–746.
Matsumura, Y. et al. 1988. Involvement of the kinin generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res. 79: 1327–1334.
Simon, R. et al. 1997. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 89: 1138–1147.
Kamishohara, M. et al. 1994. Antitumor activity of a spicamycin derivative, KRN5500 and its active metabolite in tumor cells. Oncol Res. 6: 383–390.
Yokoyama, M. et al. 1998. Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size. J Controlled Release. 55: 219–229.
Matsumura, Y. et al. 1999. Reduction of the side effect of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res. 90: 122–128.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Yasuhiro, M. (2002). DDS in Cancer Chemotherapy. In: Chiellini, E., Sunamoto, J., Migliaresi, C., Ottenbrite, R.M., Cohn, D. (eds) Biomedical Polymers and Polymer Therapeutics. Springer, Boston, MA. https://doi.org/10.1007/0-306-46842-5_4
Download citation
DOI: https://doi.org/10.1007/0-306-46842-5_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46472-0
Online ISBN: 978-0-306-46842-1
eBook Packages: Springer Book Archive